IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Israel.
IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Israel.
Fertil Steril. 2022 Jun;117(6):1291-1299. doi: 10.1016/j.fertnstert.2022.02.025. Epub 2022 Feb 25.
To assess the influence of coronavirus disease 2019 (COVID-19) messenger ribonucleic acid vaccine on ovarian response and in vitro fertilization (IVF) treatment outcomes.
A retrospective cohort study.
A tertiary university-affiliated medical center and a private medical center.
PATIENT(S): The study included a total of 400 patients, 200 vaccinated women and 200 age-matched unvaccinated women, who underwent IVF in January-April 2021.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): The mean number of oocytes retrieved and clinical pregnancy rates in vaccinated vs. unvaccinated patients.
RESULT(S): A total of 200 patients underwent oocyte retrieval 14-68 days after receiving COVID-19 vaccination. No difference was found in the mean number of oocytes retrieved per cycle (10.63 vs. 10.72) between vaccinated and unvaccinated patients. Among 128 vaccinated and 133 unvaccinated patients who underwent fresh embryos transfers, no difference was demonstrated in the clinical pregnancy rates (32.8% vs. 33.1%), with 42 and 44 clinical pregnancies, respectively. The fertilization rates and mean number of cryopreserved embryos were similar between the 2 groups in freeze-all cycles (55.43% vs. 54.29% and 3.59 vs. 3.28, respectively). Among vaccinated and unvaccinated patients who underwent fresh embryo transfers, no difference was noted in the fertilization rate (64.81% vs. 61.98%) and transferred embryos' quality. Regression models applied demonstrated no effect of the vaccine on oocyte yields and pregnancy rates.
CONCLUSION(S): The COVID-19 messenger ribonucleic acid vaccine did not affect the ovarian response or pregnancy rates in IVF treatment. Women should be vaccinated for COVID-19 before attempting to conceive via IVF treatments, given the higher risk of severe illness in pregnant women.
评估 2019 年冠状病毒病(COVID-19)信使核糖核酸疫苗对卵巢反应和体外受精(IVF)治疗结局的影响。
回顾性队列研究。
一所三级大学附属医院和一家私立医疗中心。
这项研究共纳入了 400 名患者,其中 200 名接受了 COVID-19 疫苗接种的女性和 200 名年龄匹配的未接种疫苗的女性,她们于 2021 年 1 月至 4 月接受了 IVF。
无。
接种组和未接种组患者的平均获卵数和临床妊娠率。
共有 200 名患者在接种 COVID-19 疫苗后 14-68 天进行了取卵。接种组和未接种组患者的每周期平均获卵数(10.63 枚比 10.72 枚)无差异。在 128 名接受新鲜胚胎移植的接种组患者和 133 名未接种组患者中,临床妊娠率(32.8%比 33.1%)、分别有 42 例和 44 例临床妊娠)无差异。在所有冷冻胚胎移植周期中(55.43%比 54.29%和 3.59 比 3.28),两组的受精率和平均冷冻胚胎数相似。在接受新鲜胚胎移植的接种组和未接种组患者中,受精率(64.81%比 61.98%)和移植胚胎质量无差异。应用回归模型表明,疫苗对卵子产量和妊娠率没有影响。
COVID-19 信使核糖核酸疫苗不会影响 IVF 治疗中的卵巢反应或妊娠率。鉴于孕妇患重病的风险较高,因此建议女性在尝试通过 IVF 治疗受孕之前接种 COVID-19 疫苗。